425: VERAXA Biotech to Showcase Novel Cancer Therapy Platform at Key Industry Conferences Ahead of NASDAQ Listing

VERAXA Biotech, the proposed de-SPAC target of Voyager Acquisition Corp., announced its attendance at major industry conferences to highlight its BiTAC technology and growth plans, following the signing of a definitive business combination agreement.

Summary

• VERAXA Biotech AG, the proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH), will attend the ASCO Annual Meeting (May 30 June 3, 2025) and BIO International Convention (June 16 19, 2025).
• The company plans to meet with potential partners and investors, showcase its Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, and share growth plans as it prepares for a NASDAQ listing later this year.
• VERAXA's BiTAC platform is designed to develop highly specific dual-target oncology therapies, including next-generation bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), aiming for less off-tumor toxicity and enhanced tumor specificity.
• The company currently has nine discovery and development programs underway.
• Voyager Acquisition Corp. and its capital markets advisor, Cantor Fitzgerald, will accompany VERAXA at these conferences.
• A definitive business combination agreement between VERAXA and Voyager was signed on April 22, 2025, with VERAXA expected to become a publicly traded company on NASDAQ upon closing.

Sentiment

Score: 8

Explanation: The document conveys a highly positive and promotional sentiment, announcing significant corporate milestones (definitive merger agreement, upcoming NASDAQ listing) and strategic activities (conference attendance to showcase technology and attract partners/investors). It highlights a promising technology platform and growth plans, aiming to generate strong interest.

Positives

• VERAXA is actively engaging with the industry by attending major conferences (ASCO and BIO) to increase visibility and attract partnerships/investments.
• The company is showcasing its novel BiTAC platform, which offers a differentiated approach to oncology therapies with potential for enhanced tumor specificity and reduced toxicity.
• VERAXA has a robust pipeline with nine discovery and development programs, indicating active R&D.
• The signing of a definitive business combination agreement with Voyager Acquisition Corp. provides a clear path to becoming a publicly traded company on NASDAQ.
• Retention of Cantor Fitzgerald as a capital markets advisor suggests strong support for the proposed business combination and future capital market activities.

Risks

• The Business Combination Agreement could be terminated due to various unforeseen events or circumstances.
• Potential legal proceedings may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination.
• Inability to complete the Business Combination due to failure to obtain necessary shareholder consents/approvals, secure financing, or satisfy other closing conditions.
• Delays in obtaining, or adverse conditions contained in, required regulatory approvals could hinder the completion of the transaction.
• Changes to the proposed structure of the Business Combination may be required by applicable laws, regulations, or as a condition for regulatory approval.
• Projections, estimates, and forecasts of revenue, financial metrics, market opportunity, and the estimated implied enterprise value of VERAXA may not be realized.
• VERAXA's ability to scale and grow its business as anticipated is subject to various uncertainties.
• Challenges in sourcing and retaining key talent could impact VERAXA's operations and growth.
• The cash position of VERAXA following the closing of the Business Combination may differ from expectations.
• The combined entity may face difficulties in meeting stock exchange listing standards post-consummation of the Business Combination.
• The Business Combination itself could disrupt VERAXA's current plans and operations.
• The anticipated benefits of the Business Combination may not be fully recognized, potentially affected by competition, growth management, maintaining key relationships, and retaining management/employees.
• Significant costs related to the Business Combination could impact financial performance.
• Changes in applicable laws, regulations, and broader political and economic developments could adversely affect the company.
• VERAXA may be adversely affected by other economic, business, and/or competitive factors not currently foreseen.
• VERAXA's estimates of expenses and profitability may prove inaccurate.
• Failure to realize estimated shareholder redemptions, purchase price, and other adjustments could impact the transaction's financial outcome.
• Additional unknown or currently immaterial risks could cause actual results to differ materially from forward-looking statements.

Future Outlook

VERAXA is preparing for a NASDAQ listing later this year following the closing of its business combination with Voyager Acquisition Corp. The company aims to rapidly advance its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond, anticipating significant growth and benefits from the Business Combination.

Management Comments

• Christoph Antz, CEO of VERAXA, along with other leadership team members, will be meeting with potential partners and investors, showcasing the BiTAC platform, and sharing the company's growth plans.
• VERAXA states, "At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats."
• VERAXA highlights, "Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond."
• VERAXA emphasizes its foundation: "VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technologies."
• Voyager Acquisition Corp. describes its mission: "to revolutionize the healthcare sector through a merger, stock purchase, or business combination."
• Voyager highlights its team's expertise: "unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections."
• Voyager commits to: "not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry."

Industry Context

This announcement positions VERAXA Biotech within the highly active and competitive oncology therapeutics space, specifically focusing on next-generation antibody-based therapies like bispecific ADCs and T-cell engagers, which are key areas of innovation for targeted cancer treatment. The proposed de-SPAC transaction with Voyager Acquisition Corp. reflects the ongoing trend of special purpose acquisition companies seeking to merge with promising private companies, particularly in the high-growth healthcare and biotechnology sectors, to bring them to public markets. Attending major industry conferences like ASCO and BIO is a standard and crucial step for biotech companies to gain visibility, attract investment, and forge strategic partnerships.

Legal Proceedings

• The document mentions the risk of "any legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination and any definitive agreements with respect thereto."

Stakeholder Impact

• **Shareholders (Voyager Acquisition Corp.)**: Will be required to vote on the proposed Business Combination, and their investment will transition from a SPAC to a direct holding in VERAXA Biotech upon closing.
• **Potential Investors**: The announcement and conference attendance aim to attract new investors to VERAXA, particularly as it prepares for its NASDAQ listing.
• **Employees (VERAXA Biotech)**: The merger and public listing could bring new opportunities, but also potential disruption to current plans and operations.
• **Potential Partners**: VERAXA's presence at major conferences and showcasing of its BiTAC platform is intended to attract new collaboration opportunities for drug development.
• **Regulatory Authorities**: The Business Combination is subject to obtaining necessary regulatory approvals, which could impact the timeline and structure of the transaction.

Next Steps

• VERAXA Biotech will attend the ASCO Annual Meeting from May 30 to June 3, 2025.
• VERAXA Biotech will attend the BIO International Convention from June 16 to June 19, 2025.
• VERAXA is expected to list on NASDAQ later this year upon the closing of the Business Combination.
• Voyager and/or VERAXA intend to file relevant materials with the SEC, including a Registration Statement (proxy statement/prospectus).
• The definitive proxy statement and other relevant materials will be mailed or made available to Voyager stockholders for voting on the proposed transaction.

Key Dates

Recommendation

Keywords

VERAXA Biotech, Voyager Acquisition Corp, SPAC, BiTAC, oncology, cancer therapies, bispecific antibody-drug conjugates, ADCs, T-cell engagers, TCEs, NASDAQ listing, ASCO Annual Meeting, BIO International Convention, healthcare, biotechnology, de-SPAC